Skip to main content

Table 1 General Characteristics of Patients with COVID-19

From: Safety and efficacy of convalescent plasma for severe COVID-19: a randomized, single blinded, parallel, controlled clinical study

Variable

Standard therapy (n = 45)

Plasma recipients (n = 46)

P valuea

Demographics

   

Sex (%)

0.8210

Female

14 (31.1)

13 (28.3)

 

Male

31 (68.9)

33 (71.7)

 

Age (Median—IQR)

54 (48—59)

55.5 (38—62.8)

0.8333

BMI (Median—IQR)

28.2 (26.1—30.5)

30.9 (27.8—35.2)

0.0011

Therapy (%)

Corticosteroids

43 (95.6%)

45 (97.8%)

0.6166

Antibiotics

22 (48.9%)

22 (47.8%)

1.0000

NSAIDs

0 (0.0%)

1 (2.2%)

1.0000

Heparin

42 (93.3%)

45 (97.8%)

1.0000

Clinical characteristics

   

WHO scale (%)

  

0.8202

4 points

30/44 (68.2)

32/45 (71.1)

 

5 points

14/44 (31.8)

13/45 (28.9)

 

Log viral load (Estimated mean—SE)

6.4 (0.57)

5.63 (0.58)

1.0000

4C Mortality score (Median—IQR)

6 (5 – 9)

7 (5.3 – 9)

0.4850

CHOSEN score (Median—IQR)

17 (16 – 31)

16.5 (10 – 23.8)

0.0965

SOFA on inclusion (Median—IQR)

2 (2—2)

2 (2—2)

0.3728

PaO2-FiO2 on inclusion (Median—IQR)

182.3 (123—233)

178 (111.6—249.7)

0.8728

Time from symptoms onset to inclusion (Days—Median—IQR)

10 (7 – 11)

10 (8 – 11)

0.2880

Time from symptoms onset to plasma transfusion (Days—Median—IQR)

-

11 (9 – 12)

-

Time from hospital admission to plasma transfusion (Days—Median—IQR)

-

2.5 (2 – 3)

-

Comorbidities (%)

Hypertension

10 (22.2)

13 (28.3)

0.6308

Dyslipidemia

12 (26.7)

20 (43.5)

0.1248

Asthma

3 (6.7)

1 (2.2)

0.3610

CKD

3 (6.7)

2 (4.3)

0.6768

Acid-peptic disease

13 (28.9)

9 (19.6)

0.3357

Diabetes

6 (13.3)

9 (19.6)

0.5737

Current smoker

1 (2.2)

2 (4.3)

1.0000

Former smoker

19 (42.2)

20 (43.5)

1.0000

Admission laboratories (Median—IQR)

Platelets × 103 per cubic millimeter

258 (211—327)

282 (223—348)

0.5596

Leucocytes

10,230 (7800—13,960)

9235 (6922.5—11,540)

0.0747

Lymphocytes

750 (590—1050)

985 (752.5—1355)

0.0080

Neutrophils

9150 (6600—12,500)

7865 (5667.5—9837)

0.0354

C reactive protein (mg/L)

78.21 (21.6—121.8)

49.30 (14.21—111.82)

0.3718

Erythrocyte sedimentation rate (mm/hr)

30 (13—44)

25 (15—45)

0.6984

Albumin (g/dL)

3.5 (3.27—3.74)

3.40 (3.21—3.68)

0.2802

Total bilirubin (µmol/L)

0.49 (0.41—0.67)

0.46 (0.30—0.66)

0.1387

Urea (mg/dL)

18.9 (14.7 – 22.8)

15.75 (14.13—23.11)

0.4436

Creatinine (mg/dL)

0.81 (0.66—0.92)

0.82 (0.7—0.95)

0.4506

Creatine kinase (U/L)

80 (47—185)

93 (50—173.3)

0.5516

D-Dimer (mg/L)

0.65 (0.33—1.06)

0.64 (0.45—1.07)

0.6031

Ferritin (ng/mL)

1199 (727.9—1921)

1399 (858—2161.5)

0.6856

Lactate dehydrogenase (U/L)

356 (294—446)

373.5 (299—441.5)

0.7002

Procalcitonin (ng/mL)

0.17 (0.11—0.37)

0.2 (0.10—0.42)

0.9968

Troponin T (ng/mL)

0.007 (0.003—0.37)

0.009 (0.005—0.34)

0.7142

  1. a p values for categorical variables obtained by Fisher's exact test. Quantitative variables were analyzed by Mann–Whitney U-test. Differences of viral load at baseline were obtained from the post hoc analysis from the generalized linear mixed model. Abbreviations: BMI: Body mass index; NSAIDs: Non-steroidal anti-inflammatory drugs; SE: Standard error; SOFA: Sequential organ failure assessment; WHO: World health organization; IQR: Interquartile range; CKD: Chronic kidney disease